[Therapeutic application for leukemia with ribozyme].
Matsushita
H
H
Kobayashi
H
H
Kizaki
M
M
Ikeda
Y
Y
D018845:CD11 Antigens / Q000378:metabolism; D050676:Core Binding Factor Alpha 2 Subunit; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D018922:HL-60 Cells / Q000473:pathology; D006801:Humans; D007938:Leukemia / Q000235:genetics / Q000628:therapy*; D009363:Neoplasm Proteins / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D016337:RNA, Catalytic / Q000737:chemistry / Q000627:therapeutic use*; D000075142:RUNX1 Translocation Partner 1 Protein; D011993:Recombinant Fusion Proteins / Q000235:genetics; D014157:Transcription Factors / Q000235:genetics; D014212:Tretinoin / Q000494:pharmacology
C107844:AML1-ETO fusion protein, human; D018845:CD11 Antigens; D050676:Core Binding Factor Alpha 2 Subunit; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D016337:RNA, Catalytic; D000075142:RUNX1 Translocation Partner 1 Protein; D011993:Recombinant Fusion Proteins; D014157:Transcription Factors; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin; D016044:Fusion Proteins, bcr-abl